Rigel Pharmaceuticals (RIGL) 10-Q2002 Q2 Quarterly report

Filed: 14 Aug 02, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: activate, activated, activation, active, activity, allergic, allergy, animal, antibody, antigen, antitumor, assay, asthmatic, began, billion, bind, binding, biochemical, block, blocking, blood, branded, cancer, capillary, carcinoma, cardiovascular, cascade, causal, cellular, characterized, characterizing, checkpoint, comply, contrast, cough, crucial, cycle, Daiichi, dampen, death, decade, deficient, degradation, destruction, deterioration, diagnosed, died, divide, division, earliest, endothelial, enhance, epithelial, evidence, exceeded, excessive, expression, extracellular, family, field, Food, formally, found, freedom, front, gather, gene, genetic, global, goal, group, hepatocellular, humoral, hyperplasia, hypertrophy, IgE, immune, immunology, implicated, inappropriate, induce, inflammation, Inoxell, interfere, intervention, intracellular, library, ligase, link, mast, mechanism, mediated, met, metabolic, mimic, neurodegenerative, oncology, oxygen, pathological, pay, people, Pharmacology, population, potent, Preliminary, principle, profiling, proliferation, proportion, protein, purpose, Ratification, receptor, release, relief, renegotiate, replication, resolved, safety, secretion, settlement, shunted, signal, signaling, site, spinout, stimulated, stop, submission, submucosa, surface, system, table, therapeutic, therapy, today, toxic, toxicity, toxicology, transduction, transformed, translation, treated, twelve, ubiquitin, uncontrolled, viral, vital, worldwide

Removed: Australia, Australian, award, aware, belief, commenced, conflict, contributorily, convertible, country, court, desire, European, execution, infringed, lengthy, oppose, overlap, preventing, proceeding, pursuit, repurchase, sought, transfer, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RIGL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

CERTIFICATION

Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. § 1350, as adopted) (the “Sarbanes-Oxley Act of 2002”), James M. Gower, the Chief Executive Officer of Rigel Pharmaceuticals, Inc. (the “Company”), and James H. Welch, the Chief Financial Officer of the Company, each hereby certifies that, to his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2002, to which this Certification is attached as Exhibit 99.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the periods covered by the Periodic Report and the results of operations of the Company for the periods covered by the Periodic Report.

This certification accompanies the Periodic Report pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

Dated:	August 14, 2002

/s/ JAMES M. GOWER		/s/ JAMES H. WELCH
James M. Gower		James H. Welch
Chief Executive Officer		Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.